Dr. Allegretti has devoted his entire training and career to cancer research, initially focusing on hematological malignancies before transitioning to solid tumors. He began his career at the Sapienza University of Rome working on human NK cells. After obtaining a Bachelor's degree in Biotechnology, he moved on to another lab within the same University where he worked on different translational studies with targeted agents, which reinforced his interest in oncology. Since getting a PhD degree in 2015, he added experiences in managing primary samples, cells and different types of molecular and cellular biology techniques through his internship. Two years later at the end of 2017, he moved to IRCCS Regina Elena National Cancer Institute where he led studies on monoclonal antibodies against the HER2 receptor by developing innovative liquid biopsy workflows from scratch. Dr. Allegretti was particularly interested in monitoring tumor evolution in different cancer settings through clinical follow-up of patients with colorectal, breast, sarcoma, lung, and thyroid carcinomas. Dr. Allegretti has been responsible for all liquid biopsy analysis of cancer patients discussed within his Molecular Tumor Board since 2019. In parallel, he manages several liquid biopsy research projects focused on breast cancer, which he considers an innovative and exciting research area.